Clinical Trial Goal
To find out:
- The highest dose of ONO-4685 that’s safe to give
- If ONO-4685 is safe and works well to treat T-cell NHL that has relapsed or is refractory
You may be able to join this trial if you:
- Are 18 years old or older
- Have T-cell NHL that has relapsed or is refractory. Some examples include:
- Angioimmunoblastic T-cell lymphoma (AITL)
- Cutaneous T-cell lymphoma (CTCL)
- Follicular T-cell lymphoma
- Mycosis fungoides
- Peripheral T-cell lymphoma (PTCL)
- Sezary syndrome
- Do not have T-cell leukemia/lymphoma (ATLL)
- Do not have lymphoma in your brain or spinal cord
- Have not been treated with a drug that blocks PD-1, PD-L1, or CTLA-4. Your doctor can tell you this
- Have not had an allogeneic (cells from a donor) blood or marrow transplant (BMT)
- Agree to have other standard tests done to see if you can be in the clinical trial
Trial Details
ONO-4685 is an antibody that targets PD-1 and CD3 on certain cells.
You’ll get:
You’ll get:
- ONO-4685 – Given as intravenous (IV) infusions
You may continue treatment for as long as the clinical trial doctors think it’s best for your health. You'll have biopsies and/or scans to see how well the treatment is working. The clinical trial doctors will check your health for up to 1 year.
The Food and Drug Administration (FDA) has not yet approved ONO-4685.
Contacts
North America Clinical Trial Support Desk, +18665877745(Toll-Free), clinical_trial@ono-pharma.com
International Clinical Trial Support Desk, +17162141777(Standard), clinical_trial@ono-pharma.com
Locations
Sponsors
lead: Ono Pharmaceutical Co. Ltd
